David Goldstein

David Goldstein


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
XZXiao Zhao
Xiao Zhao
PPPamela Psarianos
Pamela Psarianos
LGLaleh Soltan Ghoraie
Laleh Soltan Ghoraie
KYKenneth Yip
Kenneth Yip
DGDavid Goldstein
David Goldstein
FLFei-Fei Liu
Fei-Fei Liu

4 February 2014 in Head & Neck
Verified
Journal Article
Closed access
PDF file
AEAntoine Eskander
Antoine Eskander
MMMazin Merdad
Mazin Merdad
JIJonathan C. Irish
Jonathan C. Irish
SHStephen F. Hall
Stephen F. Hall
PGPatti A. Groome
Patti A. Groome
DGDavid Goldstein
David Goldstein

27 September 2014 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
EMEric Monteiro
Eric Monteiro
MSMichael C. Sklar
Michael C. Sklar
AEAntoine Eskander
Antoine Eskander
JAJohn R. de Almeida
John R. de Almeida
MSMark Shrime
Mark Shrime
DGDavid Goldstein
David Goldstein

5 April 2014 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
AEAntoine Eskander
Antoine Eskander
JIJonathan Irish
Jonathan Irish
PGPatti A. Groome
Patti A. Groome
JFJeremy Freeman
Jeremy Freeman
PGPatrick Gullane
Patrick Gullane
DGDavid Goldstein
David Goldstein

13 April 2015 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SPSamip N. Patel
Samip N. Patel
MCMarc A. Cohen
Marc A. Cohen
BGBabak Givi
Babak Givi
BDBenjamin J. Dixon
Benjamin J. Dixon
RGRalph W. Gilbert
Ralph W. Gilbert
DGDavid Goldstein
David Goldstein

14 February 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ANAnthony Nichols
Anthony Nichols
PLPencilla Lang
Pencilla Lang
EPEitan Prisman
Eitan Prisman
EBEric Berthelet
Eric Berthelet
ETEric Tran
Eric Tran
DPDavid Palma
David Palma
Background: Patients with human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPC) have substantially better treatment response and overall survival (OS) than patients with HPV-negative disease. Treatment options for HPV+ OPC can involve either a primary radiotherapy (RT) approach (± concomitant chemotherapy) or a primary surgical approach (± adjuvant radiation) with transoral surgery (TOS). These two treatment paradigms have different spectrums of toxicity. The goals of this study are to assess the OS of two de-escalation approaches (primary radiotherapy and primary TOS) compared to historical control, and to compare survival, toxicity and quality of life (QOL) profiles between the two approaches. Methods: This is a multicenter phase II study randomizing one hundred and forty patients with T1–2 N0–2 HPV+ OPC in a 1:1 ratio between de-escalated primary radiotherapy (60 Gy) ± concomitant chemotherapy and TOS ± de-escalated adjuvant radiotherapy (50–60 Gy based on risk factors). Patients will be stratified based on smoking status (< 10 vs. ≥ 10 pack-years). The primary endpoint is OS of each arm compared to historical control; we hypothesize that a 2-year OS of 85% or greater will be achieved. Secondary endpoints include progression free survival, QOL and toxicity. Discussion: This study will provide an assessment of two de-escalation approaches to the treatment of HPV+ OPC on oncologic outcomes, QOL and toxicity. Results will inform the design of future definitive phase III trials. Trial Registration: Clinicaltrials.gov identifier: NCT03210103. Date of registration: July 6, 2017, Current version: 1.3 on March 15, 2019.